Pirogov Russian National Research Medical University (formerly known as Russian State Medical University or RSMU) is a medical higher education institution in Moscow, Russia founded in 1906. It is fully accredited and recognized by Russia's Ministry of Education and Science and is under the authority of the Ministry of Health and Social Development. Named after Russian surgeon and pedagogue N.I. Pirogov (1810-1888).[citation needed].I.I.[citation needed].
Aging is characterized by progressive loss of physiological resilience accompanied by increased susceptibility to chronic diseases. Among the interconnected hallmarks of aging, cellular senescence has emerged as a central driver of systemic inflammation through the senescence-associated secretory phenotype (SASP). Senescent cells accumulate across multiple tissues with advancing age and secrete complex mixtures of cytokines, growth factors, and proteases that reshape tissue microenvironments and propagate inflammatory signaling locally and systemically. Increasing evidence indicates that SASP composition is highly heterogeneous and depends on cell lineage, metabolic state, and the nature of the senescence-inducing stressor. Recent discoveries further demonstrate that inflammatory signaling in senescent cells is sustained by multiple nucleic acid–sensing pathways, including both cGAS–STING–dependent DNA sensing and mitochondrial RNA–mediated activation of RIG-I–like receptors. Concurrently, senescent cells deploy immune-evasion mechanisms that limit clearance by cytotoxic lymphocytes and natural killer cells, facilitating their persistence within aging tissues. Accumulation of senescent cells therefore represents a critical mechanistic link between molecular damage and the systemic inflammatory state known as inflammaging. This review synthesizes current understanding of tissue-specific SASP programs across immune, vascular, metabolic, hepatic, and neural systems. Particular emphasis is placed on mechanisms that amplify local senescence into organism-wide inflammation, including endocrine signaling, extracellular vesicle trafficking, and sex-dependent modulation of senescence pathways.
OBJECTIVE:To evaluate the efficacy and safety of mesenchymal stem cell (MSC)-based therapies in improving endometrial thickness and reproductive outcomes in women with refractory thin endometrium or Asherman's syndrome. METHODS:Following PRISMA 2020 guidelines, a systematic search of PubMed, Cochrane Library, Embase, Scopus, ClinicalTrials.gov, and Google Scholar through June 2025 was performed. Eighteen clinical studies involving 323 patients were included. MSCs derived from umbilical cord, bone marrow, adipose tissue, endometrium, or menstrual blood were administered via intrauterine infusion, transmyometrial injection, or scaffold-assisted delivery. The primary outcome was change in endometrial thickness; secondary outcomes included clinical pregnancy rate, live birth rate, and miscarriage rate. RESULTS:Meta-analysis demonstrated a significant increase in endometrial thickness following MSC therapy compared to baseline or control (mean difference = 2.35 mm; 95 % CI, 1.97-2.74; p < 0.00001). Subgroup analysis showed the largest gains in endometrial- and adipose-derived MSC groups. Randomized controlled trials confirmed higher clinical pregnancy (OR = 2.72; p = 0.002) and live birth rates (OR = 2.27; p = 0.01), with a reduced miscarriage rate (OR = 0.24; p = 0.004). No serious adverse events were reported. CONCLUSION:While MSC therapy appears to be safe, its efficacy must be confirmed by large-scale randomized trials before it can be presented to the public or recommended as an effective approach for endometrial regeneration.
Background: No machine learning (ML) models for sepsis prediction have been specifically developed for patients with prolonged or chronic critical illness (PCI/CCI). Objective: This study aimed to develop and validate an ML-based sepsis prediction model for this cohort. Methods: We analyzed ICU admissions from the Russian Intensive Care Dataset (RICD, 575 patients with PCI/CCI) and two public ICU datasets from the PhysioNet (>40,000 patients with acute critical illness). Models were trained within a right-aligned prediction framework using a case-crossover-control sampling approach and a 6 h prediction window. Two strategies were evaluated: (1) a PCI/CCI-focused model trained on RICD with external testing on PhysioNet data and (2) a universal model trained on combined RICD and PhysioNet cohorts. Models were developed with tree-based algorithms (XGBoost, LightGBM, Random Forest, AdaBoost), with internal and external validation. Primary outcome was model discrimination (AUROC). Subgroup analyses were performed for sepsis phenotypes. Results: The PCI/CCI-focused XGBoost model achieved an AUROC of 0.82 in the RICD cohort but failed to generalize to external ICU populations (AUROC 0.47). A universal model trained on mixed data demonstrated reduced discrimination in PCI/CCI patients (AUROC mean difference 0.02, p = 0.0012). Respiratory rate, heart rate, body temperature, and age were among the most important features. Predictive performance was higher in hypoinflammatory sepsis phenotype (AUROC 0.84 vs. 0.81 for hyperinflammatory, p < 0.001). Despite worthless positive predictive value (up to 21%) for PCI/CCI-focused model, negative predictive value exceeded 97%. Conclusions: A right-aligned ML model tailored to PCI/CCI demonstrated strong internal performance for sepsis exclusion but limited cross-population generalizability, underscoring the need for population-specific prediction models and prospective validation before clinical application.
BACKGROUND:Distal renal tubular acidosis (dRTA) is characterized by metabolic acidosis, growth failure nephrocalcinosis, nephrolithiasis and chronic kidney disease (CKD). Previous retrospective data suggested improved outcome with adequate metabolic control, but confirmation from prospective data is lacking. Since 2019, the European dRTA registry has collected prospective data on patients with dRTA. Herein we present results of the first data analysis. METHODS:The registry is hosted as a subregistry of the European Rare Kidney Disease Network (www.ERKnet.org). In addition to the standard items of growth and plasma creatinine, additional data on plasma and urine biochemistries, genetics, treatment and clinical manifestations were collected from February 2019 through May 2024. Logistic regression analysis was used to identify predictors of CKD and impairedgrowth. RESULTS:Of the 214 patients enrolled in the registry, only 22% were >18 years at the last visit. A genetic cause was documented in 69% of patients.On average, low blood bicarbonate levels (<22 mmol/L) and hypercalciuria were observed in 42% and 25% of patients, respectively, independently from age. Multivariable analysis showed that height standard deviation score (SDS) was positively associated with serum bicarbonate levels (p=0.008) and with early diagnosis (p=0.005). Further modelling based on odds ratios indicated that height SDS increased progressively with serum bicarbonate levels until they reached 22-24 mmol/L. Patients aged >30 years had significantly lower eGFR (p<0.001) and the overall prevalence of CKD ≥stage 2 was 36%. Patients with SLC4A1 variants were at higher risk of CKD>1 (p=0.013). CONCLUSION:Our results in this primarily paediatric cohort highlight the importance of metabolic control and support increasing the blood bicarbonate level for therapy to 24 mmol/L to improve growth. Compared to the overall population, patients with dRTA are at higher risk of CKD from childhood, particularly if they have underlying SLC4A1 variants.
The combination of amyotrophic lateral sclerosis (ALS) with Alzheimer's disease is rare. Currently, it is unclear whether such comorbidity is an accidental coincidence or a manifestation of a specific pathological process. A case of simultaneous occurrence of classic symptoms of the bulbar form of ALS and Alzheimer's disease is presented. The possible mechanisms of the combination of two diseases are analyzed.